Correction: First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590

months (range, 53.8-69.7)." should have been "In total, 141 of 749… participants were enrolled in Japan.Median study follow-up was 60.6 months (range, 53.8-69.7)." 2. In Table 3, several values describing treatment-related adverse events and immune-mediated adverse events/ infusion reactions in the Japanese subgroup were incorrectly reported.For completeness and transparency, the old incorrect and correct versions are displayed below.